https://www.bbc.com/news/health-52737169
Chloroquine, hydroxychloroquine or a placebo will be given to more
than 40,000 healthcare workers from Europe, Africa, Asia and South
America.
The first UK participants in the global trial are being enrolled on
Thursday at the Brighton and Sussex University Hospitals and the John
Radcliffe Hospital in Oxford.
They will be given either
hydroxychloroquine or a placebo for three months. At sites in Asia,
participants will be given chloroquine or a placebo.
These are the first of a planned 25 UK sites, with results expected by the end of the year.
One of the study's leaders, Prof Nicholas White at the University of
Oxford said: "We really do not know if chloroquine or hydroxychloroquine
are beneficial or harmful against Covid-19."
While the University of Oxford trial is taking place in a controlled
clinical environment, the World Health Organization has warned that some
individuals were self-medicating and risked causing themselves serious
harm.
It has not yet been shown to be safe and effective in the
prevention or treatment of coronavirus and can cause dangerous heart
arrhythmias.
The trial also involves researchers from the UK, Thailand, Vietnam, Laos, Cambodia and Italy.
There is also an already-ongoing study like this being run by University of Minnesota.
ReplyDeleteDespite CNN's histrionics, the idea of HCQ as prophylaxis for healthcare workers at high risk has been rumbled about since the idea of HCQ as a covid therapy. (and indeed some docs in NY have attempted this since long ago). Much like its use as a therapeutic, it's all just the realm of idea until someone actually demonstrates it. Hopefully trials can be run quickly and determine whether this works or whether it's useless garbage and we can move on either way